# Sorafenib Monotherapy vs. TACE-sorafenib Sequential Therapy for HCC With Metastasis

> **NCT03518502** · PHASE4 · UNKNOWN · sponsor: **Korea University** · enrollment: 130 (estimated)

## Conditions studied

- Hepatocellular Carcinoma
- Metastasis

## Interventions

- **PROCEDURE:** transarterial chemoembolization (TACE)
- **DRUG:** Sorafenib

## Key facts

- **NCT ID:** NCT03518502
- **Lead sponsor:** Korea University
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2012-03-01
- **Primary completion:** 2020-02-28
- **Final completion:** 2022-02-28
- **Target enrollment:** 130 (ESTIMATED)
- **Last updated:** 2018-05-08

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03518502

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03518502, "Sorafenib Monotherapy vs. TACE-sorafenib Sequential Therapy for HCC With Metastasis". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT03518502. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*